Lone Wolf Saturday, 09/23/17 06:30:25 PM Re: Marilynt post# 169 Post # of 814 There were a few things the markets didn't seem to care about / factor in Friday. Trading was all about downside momentum. Here are the issues that should be factored in going forward...and explains the multiple unchanged ratings from the financial institutions: 1- cash on hand = a PPS of $4 2- A major Japanese Pharma had given them a 40mil upfront payment and has milestone payments in place for the future. 3- company can be approved for the drugs abroad...Japan likely first in line. Perhaps the most important is the following...company's drug IS successful. The phase III results released Friday compared the daily dosage results of Pfizer's drug to VSAR's bi-monthly drug! That's crazy!! It's like comparing apples to oranges. Okay...that said...company should come out on Monday and emphasize that they still plan on submitting this for approval...again...it's a proven successful drug with no difference in side effects. Lastly...I won't say who, what, where or how I know...ill just say the markets should 'drill down' and give some thought to what the response has been from parents whose children were involved in the clinical trials...if they do, they will see it speaks volumes about what the parents of the children receiving the drug feel about it and its effectiveness compared to the daily dosage drug. Watch this end up being a take-over candidate if current prices remain what they are.